Developments from THESE 4 Breast Cancer Stocks in 2022 are Turning Heads March 15, 2022 - Baystreet.ca VANCOUVER –According to a new report from ResearchAndMarkets.com, the Global Breast Cancer Drug Market is set to hit US$27.04 billion by 2026, growing at a CAGR growth of 8.6%. Meanwhile Global Markets Insights Inc. has projected that the breast cancer therapeutics market is expected to hit $42.6 billion by 2028. So far in 2022, there’s been a lot of positive news from biotech developers fighting breast cancer, including THESE 4 stocks: Pfizer, Inc. (NYSE:PFE), AstraZeneca PLC (NASDAQ:AZN), Gilead Sciences, Inc. (NASDAQ:GILD), and Puma Biotechnology, Inc. (NASDAQ:PBYI). Pfizer, Inc. (NYSE:PFE) Pfizer produces both cancer-fighting drugs paclitaxel (Taxol) and avelumab (Bavencio) with partners Merck KGaA and Merck Serono respectively. These two are currently being studied in combination with a immunotherapy agent called pelareorep in a phase 2 HR+/HER2- metastatic breast cancer trial called BRACELET-1, which is on track for top-line data in Q4 2022. A corresponding bridging clinical trial is taking place to satisfy Chinese regulatory requirements and thereby accelerate pelareorep's development in territories that include China, Hong Kong, and Macau. Results from the trial in Asia are expected to include data from the randomized North American metastatic breast cancer trials in future submissions to regulators in China and its territories. AstraZeneca PLC (NASDAQ:AZN) Shares of AstraZeneca rose upon the release of positive results for its breast cancer treatment, Enhertu—developed with partners Daiich Sankyo. "Today’s historic news from DESTINY-Breast04 could reshape how breast cancer is classified and treated,” said Susan Galbraith, AstraZeneca Executive VP of Oncology R&D. “A HER2-directed therapy has never-before shown a benefit in patients with HER2-low metastatic breast cancer. These results for ENHERTU are a huge step forward and could potentially expand our ability to target the full spectrum of HER2 expression, validating the need to change the way we categorize and treat breast cancer." The latest Enhertu results open up a new treatment option for roughly 55% of patients whose breast cancer isn’t tied to high levels of a specific protein. Gilead Sciences, Inc. (NASDAQ:GILD) Gilead Sciences recently revealed new results from its TROPiCS-02 study for its drug Trodelvy, which outperformed chemotherapy at staving off disease progression or death in heavily pretreated patients with HR-positive, HER2-negative metastatic breast cancer. “Trodelvy demonstrated consistent activity in this difficult-to-treat patient population,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. “We are evaluating the data and will explore potential pathways with regulatory authorities to bring Trodelvy to this group of patients.” In the overall HR-positive, HER-negative breast cancer population, Trodelvy could potentially reach $2.2 billion in peak worldwide sales if it shows good efficacy and safety profiles, according to RBC Capital Markets analyst Brian Abrahams. Puma Biotechnology, Inc. (NASDAQ:PBYI) Puma recently updated the market on its operations, including the state of its fight against breast cancers, including the presentation of data from the SUMMIT trial at the 2021 San Antonio Breast Cancer Symposium, and the ongoing commitment to provide neratinib (NERLYNX®) to patients with HER2+ breast cancer. Earlier in the year, Puma announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of breast cancer were updated for 2022 to include two important changes involving neratinib. First, neratinib (NERLYNX®) was added to the body of the guidelines for the treatment of adjuvant HER2-positive Breast Cancer (BINV-L) under the heading Useful in Certain Circumstances, with a recommendation for considering extended adjuvant neratinib for patients with HR-positive, HER2-positive disease with a perceived high risk of recurrence. Next, the NCCN included dose escalation as an approach to improve the tolerability of neratinib in the treatment of adjuvant HER2-positive Breast Cancer (BINV-L).
Developments from THESE 4 Breast Cancer Stocks in 2022 are Turning Heads March 15, 2022 - Baystreet.ca VANCOUVER –According to a new report from ResearchAndMarkets.com, the Global Breast Cancer Drug Market is set to hit US$27.04 billion by 2026, growing at a CAGR growth of 8.6%. Meanwhile Global Markets Insights Inc. has projected that the breast cancer therapeutics market is expected to hit $42.6 billion by 2028. So far in 2022, there’s been a lot of positive news from biotech developers fighting breast cancer, including THESE 4 stocks: Pfizer, Inc. (NYSE:PFE), AstraZeneca PLC (NASDAQ:AZN), Gilead Sciences, Inc. (NASDAQ:GILD), and Puma Biotechnology, Inc. (NASDAQ:PBYI). Pfizer, Inc. (NYSE:PFE) Pfizer produces both cancer-fighting drugs paclitaxel (Taxol) and avelumab (Bavencio) with partners Merck KGaA and Merck Serono respectively. These two are currently being studied in combination with a immunotherapy agent called pelareorep in a phase 2 HR+/HER2- metastatic breast cancer trial called BRACELET-1, which is on track for top-line data in Q4 2022. A corresponding bridging clinical trial is taking place to satisfy Chinese regulatory requirements and thereby accelerate pelareorep's development in territories that include China, Hong Kong, and Macau. Results from the trial in Asia are expected to include data from the randomized North American metastatic breast cancer trials in future submissions to regulators in China and its territories. AstraZeneca PLC (NASDAQ:AZN) Shares of AstraZeneca rose upon the release of positive results for its breast cancer treatment, Enhertu—developed with partners Daiich Sankyo. "Today’s historic news from DESTINY-Breast04 could reshape how breast cancer is classified and treated,” said Susan Galbraith, AstraZeneca Executive VP of Oncology R&D. “A HER2-directed therapy has never-before shown a benefit in patients with HER2-low metastatic breast cancer. These results for ENHERTU are a huge step forward and could potentially expand our ability to target the full spectrum of HER2 expression, validating the need to change the way we categorize and treat breast cancer." The latest Enhertu results open up a new treatment option for roughly 55% of patients whose breast cancer isn’t tied to high levels of a specific protein. Gilead Sciences, Inc. (NASDAQ:GILD) Gilead Sciences recently revealed new results from its TROPiCS-02 study for its drug Trodelvy, which outperformed chemotherapy at staving off disease progression or death in heavily pretreated patients with HR-positive, HER2-negative metastatic breast cancer. “Trodelvy demonstrated consistent activity in this difficult-to-treat patient population,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. “We are evaluating the data and will explore potential pathways with regulatory authorities to bring Trodelvy to this group of patients.” In the overall HR-positive, HER-negative breast cancer population, Trodelvy could potentially reach $2.2 billion in peak worldwide sales if it shows good efficacy and safety profiles, according to RBC Capital Markets analyst Brian Abrahams. Puma Biotechnology, Inc. (NASDAQ:PBYI) Puma recently updated the market on its operations, including the state of its fight against breast cancers, including the presentation of data from the SUMMIT trial at the 2021 San Antonio Breast Cancer Symposium, and the ongoing commitment to provide neratinib (NERLYNX®) to patients with HER2+ breast cancer. Earlier in the year, Puma announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of breast cancer were updated for 2022 to include two important changes involving neratinib. First, neratinib (NERLYNX®) was added to the body of the guidelines for the treatment of adjuvant HER2-positive Breast Cancer (BINV-L) under the heading Useful in Certain Circumstances, with a recommendation for considering extended adjuvant neratinib for patients with HR-positive, HER2-positive disease with a perceived high risk of recurrence. Next, the NCCN included dose escalation as an approach to improve the tolerability of neratinib in the treatment of adjuvant HER2-positive Breast Cancer (BINV-L).